-+ 0.00%
-+ 0.00%
-+ 0.00%

BofA Securities Keeps UCB at Buy

MT Newswires·09/24/2026 08:07:14
Listen to the news
08:07 AM EDT, 09/24/2026 (MT Newswires) -- BofA Securities on Thursday maintained its buy rating on biopharmaceutical company UCB (UCB.BR), with a price target of 280.00 euros. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)